Access of black, hispanic, and nonprivately insured women to liquid-Based cytology, human papillomavirus DNA testing, and On-Site colposcopy in the united states

Journal of Lower Genital Tract Disease

Volumn 13, Issue 1, 2009, Pages 17-27

  Hoover, Karen ^a,c   Koumans, Emilia H ^a   Montaño, Daniel ^b   Kasprzyk, Danuta ^b   Freeman, Crystal ^b   Greek, April ^b   Jain, Nidhi ^a   Irwin, Kathleen ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b BATTELLE MEMORIAL INSTITUTE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Access; Colposcopy; HPV test; Liquid based cytology; Pap test

Indexed keywords

ADULT; AFRICAN AMERICAN; ARTICLE; CANCER SCREENING; CLINICAL PRACTICE; COLPOSCOPY; CYTOLOGY; DNA DETERMINATION; ETHNICITY; FEMALE; HEALTH INSURANCE; HISPANIC; HUMAN; MALE; PAPANICOLAOU TEST; PATIENT CARE; UNITED STATES; UTERINE CERVIX CANCER; WART VIRUS;

AFRICAN AMERICANS; COLPOSCOPY; CYTOLOGY; DNA VIRUSES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HISPANIC AMERICANS; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; UNITED STATES; VAGINAL SMEARS;

EID: 58549095128     PISSN: 10892591     EISSN: None     Source Type: Journal    
DOI: 10.1097/LGT.0b013e318194b87e     Document Type: Article

References (46)

1. Saraiya M, Ahmed F, Krishnan S, Richards TB, Unger ER, Lawson HW. Cervical cancer incidence in a prevaccine era in the United States, 1998-2002. Obstet Gynecol 2007; 109:360-70.
2. Surveillance, Epidemiology, and End Results. Cancer Stat Fact Sheets, Cancer of the Cervix Uteri. Available at http://seer.cancer.gov/statfacts/html/ cervix.html. Accessed March 17, 2008.
3. May berry RM, Mili F, Ofili E. Racial and ethnic differences in access to medical care. Med Care Res Rev 2000; 57(suppl l):108-45.
4. Coughlin SS, Uhler RJ. Breast and cervical cancer screening practices among Hispanic women in the United States and Puerto Rico, 1998-1999. Prev Med 2002; 34:242-51.
5. Selvin E, Brett KM. Breast and cervical cancer screening: sociodemographic predictors among white, black, and Hispanic women. Am J Public Health 2003;93:618-23.
6. Echeverria SE, Carrasquillo O. The roles of citizenship status, acculturation, and health insurance in breast and cervical cancer screening among immigrant women. Med Care 2006;44:788-92.
7. Cannistra SA, Niloff JM. Cancer of the uterine cervix. N Engl J Med 1996;334:1030-8.
8. Leyden WA, Manos MM, Geiger AM, Weinmann S, Mouchawar J, Bischoff K, et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst 2005;97:675-83.
9. Stuart GC, McGregor SE, Duggan MA, Nation JG. Review of the screening history of Alberta women with invasive cervical cancer. CMAJ 1997;157:513-9.
10. Sung HY, Kearney KA, Miller M, Kinney W, Sawaya GF, Hiatt RA. Papanicolaou smear history and diagnosis of invasive cervical carcinoma among members of a large prepaid health plan. Cancer 2000;88:2283-9.
11. Irwin K, Montano D, Kasprzyk D, Carlin L, Freeman C, Barnes R, et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol 2006; 108:397-409.
12. Noller KL, Bettes B, Zinberg S, Schulkin J. Cervical cytology screening practices among obstetrician-gynecologists. Obstet Gynecol 2003;102:259-65.
13. Sawaya GF. Evidence-based medicine versus liquid-based cytology. Obstet Gynecol 2008;111:2-3.
14. Yabroff KR, Kerner JF, Mandelblatt JS. Effectiveness of interventions to improve follow-up after abnormal cervical cancer screening. Prev Med 2000;31:429-39.
15. Basen-Engquist K, Paskett ED, Buzaglo J, Miller SM, Schover L, Wenzel LB, et al. Cervical cancer. Cancer 2003; 98(9 suppl):2009-14.
16. Khanna N, Phillips MD. Adherence to care plan in women with abnormal Papanicolaou smears: a review of barriers and interventions. J Am Board Fam Pract 2001; 14:123-30.
17. Hart LG, Larson EH, Lishner DM. Rural definitions for health policy and research. Am J Public Health 2005; 95:1149-55.
18. Benard VB, Lee NC, Piper M, Richardson L. Race-specific results of Papanicolaou testing and the rate of cervical neoplasia in the National Breast and Cervical Cancer Early Detection Program, 1991-1998 (United States). Cancer Causes Control 2001;12:61-8.
19. Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a meta-analysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001;185:308-17.
20. del Carmen MG, Montz FJ, Bristow RE, Bovicelli A, Cornelison T, Trimble E. Ethnic differences in patterns of care of stage 1A(1) and stage 1A(2) cervical cancer: a SEER database study. Gynecol Oncol 1999;75:113-7.
21. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95:46-52.
22. Benard VB, Lawson HW, Eheman CR, Anderson C, Helsel W. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet Gynecol 2005;105:1323-8.
23. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002;52:342-62.
24. Schiffman M, Castle PE. When to test women for human papillomavirus. BMJ 2006;332:61-2.
25. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet Gynecol 2008;111:167-77.
26. Ronco G, Cuzick J, Pierotti P, Cariaggi MP, Dalla Palma P, Naldoni C, et al. Accuracy of liquid based versus conventional cytology: overall results of new technologies for cervical cancer screening: randomised controlled trial. BMJ 2007;335:28.
27. Sherman ME. Chapter 11: future directions in cervical pathology. J Natl Cancer Inst Monogr 2003;(31):72-9.
28. Wright TC Jr, Massad LS, Dunton CJ, Spitzer M, Wilkinson EJ, Solomon D. 2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests. Am J Obstet Gynecol 2007;197:346-55.
29. Rappaport KM, Forrest CB, Holtzman NA. Adoption of liquid-based cervical cancer screening tests by family physicians and gynecologists. Health Serv Res 2004;39(4 Pt 1):927-47.
30. Sawaya GF, Sox HC. Trials that matter: liquid-based cervical cytology: disadvantages seem to outweigh advantages. Ann Intern Med 2007;147:668-9.
31. Screening for Cervical Cancer, Summary of Recommendations. Available at http://www.ahrq.gov/clinic/uspstf/uspscerv.htm. Accessed March 17, 2008.
32. Solomon D, Schiffman M, Tarone R. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9.
33. ACOG Practice Bulletin number 66, September 2005. Management of abnormal cervical cytology and histology. Obstet Gynecol 2005;106:645-64.
34. Wright TC Jr, Schiffman M, Solomon D, Cox JT, Garcia F, Goldie S, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004;103:304-9.
35. Wright TC Jr, Schiffman M. Adding a test for human papillomavirus DNA to cervical-cancer screening. N Engl J Med 2003;348:489-90.
36. ACOG Practice Bulletin: clinical management guidelines for obstetrician-gynecologists. Number 45, August 2003. Cervical cytology screening (replaces committee opinion 152, March 1995). Obstet Gynecol 2003;102:417-27.
37. Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-88.
38. Kulasingam SL, Kim JJ, Lawrence WF, Mandelblatt JS, Myers ER, Schiffman M, et al. Cost-effectiveness analysis based on the atypical squamous cells of undetermined significance/low-grade squamous intraepithelial lesion Triage Study (ALTS). J Natl Cancer Inst 2006;98:92-100.
39. Goldie SJ, Kim JJ, Wright TC. Cost-effectiveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more. Obstet Gynecol 2004; 103:619-31.
40. Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005; 97:888-95.
41. Saraiya M, Irwin KL, Carlin L, Chen X, Jain N, Benard V, et al. Cervical cancer screening and management practices among providers in the National Breast and Cervical Cancer Early Detection Program (NBCCEDP). Cancer 2007; 110:1024-32.
42. Ku L, Flores G. Pay now or pay later: providing interpreter services in health care. Health Aff (Millwood) 2005;24:435-44.
43. Kuehn BM. Poverty shift may burden health system. JAMA 2007;297:1047-8.
44. Shi L, Collins PB, Aaron KF, Watters V, Shah LG. Health center financial performance: national trends and state variation, 1998-2004. J Public Health Manag Pract 2007; 13:133-50.
45. Centers for Disease Control and Prevention. NBCCEDP, Guidance documents, NBCCEDP program component chapter overview. Available at: http:r//www.cdc.gov/ cancer/nbccedp/bccpdfs/overview.pdf. Accessed March 17, 2008.
46. Lawson HW, Henson R, Bobo JK, Kaeser MK. Implementing recommendations for the early detection of breast and cervical cancer among low-income women. MMWR Recomm Rep 2000;49(RR-2):37-55.